Results 201 to 210 of about 41,565 (267)

Correlation of Neurodegenerative Biomarkers and Functional Outcome in Patients with Relapsing-Remitting Multiple Sclerosis. [PDF]

Neurol Int
Polunosika E, Feldmane M, Pastare D, Simren J, Blennow K, Zdanovskis N, Zetterberg H, Erts R, Karelis G.   +8 more
europepmc   +1 more source

No association between the wearing-off effect and α4-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis. [PDF]

Neurotherapeutics
Freeman SA, Rual C, Biotti D, Lepetit M, Le Berre J, Ferrara K, Treiner E, Ciron J.   +7 more
europepmc   +1 more source

Adalimumab-Associated Transverse Myelitis Revealing Relapsing-Remitting Multiple Sclerosis in a Patient With Crohn's Disease: A Case Report. [PDF]

Cureus
Gawargeous SS, Elsahy T.
europepmc   +1 more source

Correction: Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia. [PDF]

Front Public Health
Al-Jedai A, Almudaiheem H, Al-Suweidan FA, Al Jumah M, Al-Thobaiti A, Alzureiqan F, Abu Ras W, Al-Dosari FM, Malik YA, Dhopte P, Ojeil R.   +10 more
europepmc   +1 more source

Teriflunomide treatment for relapsing-remitting multiple sclerosis: An experience from Saudi Arabia. [PDF]

Medicine (Baltimore)
Aljinaid M, Khojah O, Arshad L, Algahtani R, Alghweinem Z, Alshehri S, Abulaban A, Al Malik Y, Makkawi S.   +8 more
europepmc   +1 more source

Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis. [PDF]

Front Immunol
Zhao Y, Chen B, Zhao X, Yang R, He W, Li D, Sun Q, Zhang J, Liu X.   +8 more
europepmc   +1 more source

Multimodal predictors of disability progression and processing speed decline in relapsing-remitting multiple sclerosis. [PDF]

Sci Rep
Korbmacher M, Lie IA, Wesnes K, Westman E, Espeseth T, Specht K, Andreassen OA, Westlye LT, Wergeland S, Myhr KM, Torkildsen Ø, Høgestøl EA.   +11 more
europepmc   +1 more source

Metabolic changes in normal-appearing white matter associate with MRI measures of disease burden in relapsing-remitting multiple sclerosis over three years. [PDF]

Sci Rep
Zöchner A, Bogner W, Dal-Bianco A, Strasser B, Hangel G, Rommer PS, Niess E.   +6 more
europepmc   +1 more source

<i>Roseburia</i>-Associated Gut-Brain Axis Alterations in Relapsing-Remitting Multiple Sclerosis: Evidence from a Household-Matched Case-Control Study. [PDF]

Nutrients
Zollo A, Marsiglia MD, Corona A, Ottaviano E, Mazzieri MLT, Mingione A, Ancona S, Priori A, Borghi E, Boneschi FM.   +9 more
europepmc   +1 more source

Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple Sclerosis.

JAMA Netw Open
Blaylock B, Van Nuys K, Joyce G.
europepmc   +1 more source